BASF and Transinsight agree to collaborate in exploring alternatives to animal testing

BASF SE and Transinsight GmbH, a provider of semantic search technologies for Web 2.0, have agreed to establish close cooperation in the area of semantic analyses to search for alternatives to animal testing. Together with the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung BfR), both companies will expand the first specialized semantic search engine for this research area called www.Go3R.org to become a global internet platform. In the future, experts from all over the world will be able to use this platform to bring together their knowledge on alternative and supplementary methods to animal testing.

For over 20 years, BASF has been committed to establishing alternative and supplementary methods. Since 2004, the company has been developing and validating alternatives to animal testing in its own alternatives laboratory with a research budget of 2 million euros per year. Even now alternative methods are employed in 25 percent of all the company's tests. "We are striving to increase this proportion. Transinsight's semantic search supports us in this endeavour. With the help of this highly promising technology, we - just like any other potential user - can browse the internet, internal sources, patents and specialized databases much more efficiently than before when searching for information on meaningful approaches to new alternative methods", explains Dr Robert Landsiedel, Head of the Short Term Toxicology Department at BASF.

Transinsight's semantic search engine also finds related terms and web pages that are relevant for the respective search term and thus provides considerably more accurate and comprehensive search results than conventional full text search engines. "Go3R will make a tremendous contribution to improving the process of searching for information on alternative methods", states Dr Michael R. Alvers, CEO of Transinsight. "To achieve this, we are transferring the Wikipedia concept – the largest internet encyclopaedia compiled by the community – to semantic networks of terms. Currently, this is the most efficient way to achieve a large knowledge base within a short period of time and thus to significantly reduce the amount of animal testing in the long term", Alvers continues. The www.Go3R.org platform is already available online. The service is free of charge.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, AbCam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

About BASF
BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from oil and gas to chemicals, plastics, performance products, agricultural products and fine chemicals. As a reliable partner, BASF helps its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges, such as climate protection, energy efficiency, nutrition and mobility. BASF has more than 95,000 employees and posted sales of almost 58 billion euros in 2007. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...